About > News

PEGS: The Essential Protein Engineering Summit 2015, April 25-29, 2016 Boston, MA

PEGS: The Essential Protein Engineering Summit 2015, May 4-8, 2015 Boston, MA http://www.pegsummit.com Seaport World Trade Center

Harbour Antibodies Announces First U.S. Patent for Novel Transgenic Mouse Antibody Technology for Next Generation Therapeutic Antibody Discovery

Harbour Antibodies Announces First U.S. Patent for Novel Transgenic Mouse Antibody Technology for Next Generation Therapeutic Antibody Discovery Patent Covering “Heavy Chain Only” Antibody Platform Enables Discovery of Products Not Achievable with Conventional Antibody Platforms Cambridge, MA, December 19, 2014 – Harbour Antibodies BV, announced the issuance of the first U.S. Patent (No. 8,883,150) covering the company’s HCAb mouse platform for producing human “heavy chain only” antibody molecules. The antibody molecules produced by the technology have broad potential for use by Harbour’s licensees to develop products with attributes not achievable by conventional antibody platforms. “Our HCAb mouse platform is a powerful technology for generating multiple diverse heavy-chain only antibody molecules …

Princess Lilian Foundation visiting professor 2013-14 at KU Leuven: Frank Grosveld

We are delighted to inform you that Prof. Frank Grosveld (from Erasmus MC, Rotterdam) has been awarded the Princess Lilian Foundation visiting professorship 2013-14 at KU Leuven. Frank Grosveld is a world-leading expert in transcription and chromatin regulation in cell differentiation and disease, and also had his research accompanied by frontline development of multiple genome-wide omicsapproaches. Frank Grosveld will stay for 1 week in Belgium (March 16-March 22, 2014) and talk to researchers of KU Leuven and other Belgian universities. In Leuven, the opening ceremony, encompassing a public lecture by Frank Grosveld, and followed by a reception takes place on Monday, March 17, 2014 from 16:00 onwards at KU Leuven, Campus Gasthuisberg. In addition, …

Harbour Antibodies Licenses H2L2 Mice to Pfizer

Harbour Antibodies Licenses H2L2 Mice to Pfizer Harbour Antibodies, the creator of transgenic mice to aid in the development of new human therapeutic antibodies, announced today that it has licensed its H2L2 mice, which can generate human monoclonal antibodies, to Pfizer Inc. Harbour Antibodies’ transgenic H2L2 mice enable biotechs, pharmaceutical companies and academic research labs to speed new drug development by generating human antibodies using traditional hybridoma technology.  Under the licensing agreement, Pfizer will have the option to use the mice in as many projects as they wish without disclosing the nature of the projects to Harbour. This licensing deal marks the third partnership for Harbour Antibodies. Previous deals have …

Harbour News

Upcoming Events

Contact Us

Name: 
Email: 
Company: 
Message: 
Submit

Join Mailing List

Name: 
Email: 
Company: 
Submit